DYANAVEL XR
Peakamphetamine
NDAORALSUSPENSION, EXTENDED RELEASE
Approved
Oct 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9
Mechanism of Action
non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known.
Pharmacologic Class:
Central Nervous System Stimulant
Clinical Trials (5)
A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine
Started Feb 2026
A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
Started Oct 2019
430,000 enrolled
Attention Deficit Disorder With Hyperactivity
Amphetamine Induced Adult Respiratory Distress Syndrome
Started Jan 2019
49 enrolled
BurnsAcute Lung InjuryAcute Respiratory Distress Syndrome+1 more
A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)
Started Dec 2016
12 enrolled
Healthy Volunteers
Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)
Started Sep 2012
100 enrolled
Amphetamine-Related Disorders
Loss of Exclusivity
LOE Date
Sep 7, 2036
127 months away
Patent Expiry
Sep 7, 2036